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Abstract The gastrointestinal “hunger” hormone ghrelin is
the only known circulating peripheral molecule with the
ability to decrease body fat utilization and to increase body
weight gain. Accordingly, due to ghrelin’s effects to
promote food intake while decreasing energy expenditure
ghrelin may offer potential as a drug for treatment of eating/
wasting disorders and cachexia. Therapeutic potential of
ghrelin and ghrelin analogues to promote food intake and
body weight gain was recently indicated in several clinical
studies. The recent discovery of the ghrelin O-acyltransfer-
ase as the key enzyme responsible for ghrelin acylation has
further deepened our understanding of ghrelin activation,
thereby paving the way for more efficient targeting of the
ghrelin pathway. Here, we summarize the current knowl-
edge pertaining to the potential of the endogenous ghrelin
system as a drug target for the treatment of eating/wasting
disorders and cachexia.
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1 Introduction
Cachexia (Greek: kakós—bad; hexis—condition) is a
multifactorial syndrome characterized by substantial loss
of body weight due to an involuntarily wasting of skeletal
muscle and adipose tissue mass as a result of an imbalance
between catabolic and anabolic processes (Fig. 1)[ 1, 2].
Cachexia frequently develops in advanced stages of various
chronic diseases such as chronic heart failure (CHF),
chronic obstructive pulmonary disease (COPD), end-stage
renal disease (ESRD), sepsis, acquired immune deficiency
syndrome and various kinds of cancer [1, 3]. Dependent on
the type of tumor, cancer-cachexia is observed in 30–80%
of cancer patients with patients suffering from pancreatic or
gastric cancer having the highest frequency of weight loss
while patients with breast cancer, non-lymphocytic leuke-
mia, and sarcomas having the lowest [4]. Irrespective of the
underlying disease, however, cachexia is associated with a
low response to drug treatment, a poor quality of life, a
poor prognosis, and an increased mortality rate compared to
non-cachexia patients [1, 5]. Accordingly, cachexia is
believed to be the immediate cause of 10–20% of all deaths
in cancer patients [5].
Cachexia is frequently, but not necessarily, accompanied
by anorexia, defined as the loss of the desire to eat [4, 6].
Decreased energy intake due to anorexia contributes to
increased weight loss but, however, cannot solely explain
the typical metabolic changes associated with cachexia,
such as an excess release of pro-inflammatory cytokines
and an increased activity of the sympathetic nervous system
[1, 3, 4].
Cachexia is typically associated with an increased
release of pro-inflammatory cytokines, such as tumor
necrosis factor-α (TNFα), Interleukin-1ß (IL-1ß), IL-6,
and IL-8 [5]. Pro-inflammatory cytokines, especially TNFα
and IL6, act as catabolic factors in the pathogenesis of
cachexia by stimulating proteolytic pathways leading to
muscle atrophy and increased adipose tissue breakdown
(Fig. 1)[ 5]. In particular, TNFα stimulates muscle protein
breakdown, causes contractile dysfunction and inhibits
myogenesis and myogenic differentiation through activa-
tion of the nuclear factor-kappa B pathway [5, 7, 8]. TNFα
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lation of lipolysis, inhibition of adipocyte differentiation
and by increasing apoptosis in adipocytes [3, 5, 9].
Increased activity of the sympathetic nervous system is
frequently described in patients with cachexia [4, 10, 11]. In
particular, increased plasma concentrations of catechol-
amines as a result of sympathetic overactivity contribute to
body weight loss and tissue wasting by increasing energy
expenditure, stimulation of lipolysis, and stimulation of
apoptosis in skeletal muscle [3, 12].
Various previous studies have, with only limited success,
focused on the evaluation of potential drug targets for the
treatment of eating/wasting disorders and cachexia. One of
the endogenous peptides that, due to its beneficial effects
on e.g. food intake, energy expenditure, and inflammation
has recently reached scientific interest is the gastrointestinal
“hunger” hormone ghrelin. The ability of ghrelin and
ghrelin analogues to promote food intake and body weight
gain in patients with eating disorders and cachexia was
recently demonstrated in several clinical studies. The
importance of the ghrelin system in the neuroendocrine
control of energy balance has recently been highlighted in
several excellent review articles [13, 14]. The aim of this
review is to summarize the current knowledge pertaining to
the endogenous ghrelin system as a potential target for the
treatment of pathological reduced body mass, the key
clinical feature of cachexia.
1.1 Ghrelin synthesis and activation
The gastrointestinal peptide hormone ghrelin was discov-
ered in 1999 as an endogenous ligand for the growth
hormone secretagogue 1a receptor (GHS-R1a) [15]. Ghrelin
is synthesized as a 117 amino acid pre-prohormone, which
is post-translational cleaved into a 28 amino acid peptide
[16]. Ghrelin is predominantly synthesized and secreted by
X/A-like cells in the oxyntic glands of the mucosa of the
gastric fundus [17]. However, lower levels of ghrelin
expression can also be found in, e.g., the intestine,
pancreas, kidney, lung, ovaries and the brain [14]. Since
its discovery in 1999, a tremendous amount of research
efforts have focused on revealing ghrelin’s mechanisms of
action. To promote its biological action, ghrelin is acylated
on its serine 3 residue by the recently discovered
membrane-bound O-acyltransferase 4 (MBOAT4), which
was later accordingly renamed to ghrelin O-acyl-transferase
(GOAT; Fig. 2)[ 18, 19]. The observation that acyl-ghrelin
is absent in mice lacking Goat indicates that Goat is the
only enzyme capable to activate ghrelin in vivo [18].
1.2 Ghrelin-mediated regulation food intake and energy
balance
Ghrelin is secreted from the stomach into the bloodstream
under conditions of fasting, thus serving as a “hunger”
hormone that signals the gastrointestinal fuel status from
the periphery to the central nervous system in order to
stimulate food intake and to adjust energy balance through
a decrease in energy expenditure. Plasma levels of ghrelin
typically follow a circadian rhythm with a preprandial rise
which peaks directly at meal initiation followed by a
postprandial decrease to baseline levels within the first hour
after a meal [20–22]. In accordance to its role as a meal
initiation hormone, ghrelin stimulates food intake and
adiposity through stimulation of hypothalamic orexigenic
neuropeptides [23]. In the arcuate nucleus (ARC), a
hypothalamic key center in the control of energy metabo-
lism, GHS-R1a is co-expressed with the agouti-related
peptide (AgRP) and the neuropeptide Y (NPY), both
prototypic anabolic neuropeptides that promote a positive
energy balance through stimulation of food intake and by
decreasing energy expenditure [23–25]. Accordingly,
ghrelin-mediated activation of hypothalamic GHS-R1a
entails an increased expression and release of NPY and
AgRP in the ARC, thus entailing an activation of anabolic
downstream pathways that lead to a stimulation of food
intake and a decrease of energy expenditure [26–28].
Recent evidence further indicates that the ability of
GOAT-mediated ghrelin acylation depends on specific
dietary medium chain triglycerides as acylation sustrates
[29]. These findings indicate that ghrelin, in contrast to its
Fig. 1 Molecular mechanisms of cachexia. Typical metabolic changes
associated with the development of cachexia are an increased release
of pro-inflammatory cytokines as well as an overactivity of the
sympathetic nervous system, as indicated by increased plasma
concentrations of catecholamines. Both, pro-inflammatory cytokines
and catecholamines promote catabolic processes leading to skeletal
muscle and fat mass wasting, such as stimulation of lipid utilization
and skeletal muscle protein breakdown while decreasing energy intake
and increasing energy expenditure. ESRD end-stage renal disease,
CKD chronic kidney disease, CHF chronic heart failure, COPD
chronic obstructive pulmonary disease, IL6 Interleukin 6, IL8
Interleukin 8, IL1β Interleukin 1 beta, TNFα tumor necrosis factor
alpha
160 J Cachexia Sarcopenia Muscle (2010) 1:159–167commonly accepted role as a hunger hormone, might rather
serve as a nutrient sensor that signals the gastrointestinal
nutrient availability to the central nervous system.
Ghrelin further stimulates the expression and release of
growth hormone (GH) from the anterior pituitary gland and
thus indirectly triggers expression and secretion of hepatic
insulin-like growth factor-1 (IGF-1) [15, 30, 31]. Both, GH
and IGF-1 are anabolic hormones known to increase lean
body mass by stimulation of skeletal muscle growth and
inhibition of skeletal muscle protein breakdown [32–34].
During catabolic states, such as cachexia, GH further
stimulates lipolysis through increased release and oxidation
of free fatty acids which leads to decreased glucose and
protein oxidation and preservation of lean body mass [33].
The fundamental importance of the endogenous GOAT/
ghrelin system was very recently demonstrated by Zhao and
colleagues, who showed in Goat
−/− mice that ghrelin-
mediated regulation of GH release prevents death by
preserving blood glucose levels under conditions of severe
caloric restriction [35]. Other beneficial effects of ghrelin
include a decrease of body fat utilization [36]a n da
decrease of sympathetic nerve activity [37–39]. In white
adipocytes, ghrelin further stimulates the expression of fat-
storage promoting enzymes, such as lipoprotein lipase,
acetyl-CoA carboxylase α, fatty acid synthase, and
steaoryl-CoA desaturase-1 [40]. In brown adipocytes,
ghrelin dose-dependently lowers the expression of the
thermogenesis-related mitochondrial uncoupling proteins 1
and 3, presumably through ghrelin’s ability to decrease
sympathetic nerve activity [40]. Ghrelin further has been
reported to attenuate skeletal muscle and adipose tissue
wasting by decreasing the release of pro-inflammatory
cytokines, such as TNFα, IL-1ß, IL-6 and IL-8 [39–43]
while increasing the release of anti-inflammatory cytokines,
such as IL-10 [43]. In summary, these data indicate that the
endogenous GOAT/ghrelin system plays a fundamental role
in the neuroendocrine adaptation to starvation and that
modulation of the ghrelin system might be an interesting
target for the treatment of pathological reduced body weight
and tissue wasting.
Fig. 2 Ghrelin-mediated neuroendocrine alterations of energy metab-
olism. Ghrelin is secreted from the stomach and is acylated at its
serine 3 residues by the ghrelin O-acyltransferase (GOAT). Central-
mediated effects of ghrelin include (besides others) the stimulation of
food intake and the decrease of energy expenditure through
stimulation of hypothalamic neurons expressing neuropeptide Y
(NPY) and agouti-related peptide (AgRP). In the anterior pituitary
ghrelin stimulates the release of growth hormone (GH), which in turn
stimulates the release of hepatic insulin-like growth factor-1 (IGF-1).
Both, GH and IGF-1 increase lean body mass by inhibition of skeletal
muscle protein breakdown. In adipose tissue, ghrelin stimulates the
expression of genes coding for fat-storage promoting enzymes, such
as lipoprotein lipase (LPL), fatty acid synthase (FAS), acetyl-CoA
carboxylase α, and steaoryl-CoA desaturase-1 (SCD1). Either through
central or peripheral mechanisms ghrelin further inhibits the release of
pro-inflammatory cytokines, such as Interleukin (IL) 6, IL 8, IL1β and
the tumor necrosis factor α. Dashed lines indicate potential signal
pathways. ARC arcuate nucleus
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2.1 Anorexia nervosa
Anorexia nervosa (AN) is an eating disorder of unknown
etiology, typically characterized by an abnormal eating
behavior with disturbances of attitudes towards body
weight and shape [44, 45].
Several forms of ghrelin (octanoyl-, desacyl, (non-
octanoyl) acyl-ghrelin) can be found in circulation. How-
ever, for most available immunoassays it is either not well
known or not sufficiently disclosed which of those ghrelin
analogues they are binding and to which extent they are
cross reacting with other related peptides such as motilin.
Most assays reported in the literature likely measure total
ghrelin-like immunoreactivity including large amounts of
presumably inactive ghrelin peptide. Nevertheless, several
studies have shown a negative correlation between the body
mass index (BMI) and plasma levels of ghrelin in AN [46–
48]. Accordingly, plasma levels of ghrelin are elevated in
the acute phase of AN [48–52] and decline to normal values
upon weight restoration [49, 53, 54]. Compared to normal
weight healthy controls, also plasma levels of acyl-ghrelin
are elevated in patients with AN, even during all phases of
an oral glucose tolerance test [46, 48]. Some studies further
report higher plasma levels of acyl-ghrelin when compared
to BMI-matched lean women [47, 51–56] thus indicating
that impaired ghrelin sensitivity due to persistent hyper-
ghrelinemia might play a role in the pathogenesis of AN,
comparable to leptin resistance in persistently hyperlepti-
nemic obese individuals. Persistent hyperghrelinemia might
further contribute to the frequently described impairment of
the GH/IGF-1 axis in AN, as plasma levels of GH are
typically elevated while IGF-1 levels are paradoxically
decreased in patients with AN [57–60].
The orexigenic effects of ghrelin and ghrelin analogues
have been assessed in several human studies revealing that
ghrelin promotes food intake in both healthy individuals
[61–63] and patients with AN [64]. Ghrelin treatment of
anorectic individuals for 14 days (3 μg/kg twice daily)
increased energy intake by 12–36% compared to baseline
values in one study [64], although in another study, where
ghrelin was continuously infused for 300 min at rates of
5 pmol/kg/min, ghrelin failed to detect an effect on appetite,
as assessed by a visual analog scale [65]. Potential pitfalls
of these studies are, however, the limited amount of study
samples and the short duration of ghrelin treatment.
Notably, however, both studies report no adverse side
effects of ghrelin treatment [64, 65]. A further beneficial
effect of ghrelin treatment in AN include an increase of
blood glucose levels [66] which is in accordance with
recent findings indicating that ghrelin prevents death by
preservation of normoglycemia in Goat
−/− mice under
conditions of starvation [35].
3 Cancer-cachexia
Several animal studies have recently assessed the potential
of ghrelin in the treatment of cancer-cachexia [67–70].
Plasma concentrations of ghrelin rise with the progression
of cachexia in mice inoculated with human melanoma
cells [68] and ghrelin treatment of these mice attenuates
cachexia by stimulation of food intake and suppression of
body weight loss [67]. Similar improvements on food
intake and body weight gain were reported in tumor-
implanted rats treated with either ghrelin or the ghrelin
analog BIM-28131 [70]. In the latter study, ghrelin
increased the hypothalamic expression of AgRP and NPY
whereas, interestingly, plasma levels of GH were un-
changed [70]. However, not all studies were able to
replicate this finding [68]. It is further noteworthy that
no differences in tumor size have been observed between
ghrelin and saline treated animals [67, 70].
In accordance to the animal studies, plasma concen-
trations of ghrelin are elevated in patients with cancer-
cachexia when compared to those without cachexia [71,
72]. Continuous infusion of ghrelin (5 pmol/kg/min for
180 min) in patients with breast and colon cancer increased
energy intake by 31% compared to saline treated controls
[73]. However, in a 2-week randomized, double blind,
placebo-controlled trial, where ghrelin was given intrave-
nously at two time points at doses of 2 or 8 μg/kg, ghrelin
failed to affect nutritional intake despite elevated plasma
levels of GH indicated an increased ghrelin activity [74].
Notably, however, both studies report no adverse side
effects of ghrelin treatment [73, 74].
Noteworthy is that not all studies report elevated levels
of ghrelin in patients with advanced cancer and weight loss.
In one study, where ghrelin was measured in 30 patients
with different malignancies and 27 healthy controls, ghrelin
levels were reported to be lower in patients with advanced
cancer as compared to the healthy controls [75]. Further
studies in other study samples are required to clarify this
observation but the reduction of ghrelin levels might be
attributed to the severity and progression of the disease.
Even though substantial evidence indicates the safety
and tolerability of ghrelin at doses up to 10 μg/kg [62, 73,
74, 76], no long-term studies are available pertaining to the
potential implication of the ghrelin/GH/IGF-1 axis on
tumor growth and carcinogenesis. Both, ghrelin and/or the
ghrelin receptor are expressed in various tumorous tissues,
especially in tumors of the gastrointestinal tract, such as in
gastric endocrine tumors [77, 78], intestinal endocrine
tumors [77, 78], pancreatic endocrine tumors [79, 80] but
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tumors [83] and testicular tumors [84]. It remains unknown
as and to what extend ghrelin secretion from these tumors
affects tumor growth and/or energy balance. Increased
ghrelin secretion from tumorous tissues might be implicated
in either promoting or inhibiting tumor growth via
autocrine/paracrine pathways [13]. On the other hand,
ghrelin released from tumors might counteract skeletal
muscle and fat mass wasting by stimulation of food intake
and activation of anabolic pathways. Tumor-related alter-
ations of ghrelin secretion might thus contribute to the
different rates of weight loss, which are typically observed
in different kinds of cancers.
4 Chronic obstructive pulmonary disease
Cachexia is frequently described in patients with advanced
stages of COPD [11, 85–87] and is considered as an
independent risk factor for mortality in these patients [87,
88]. Plasma levels of ghrelin are negatively correlated with
BMI in COPD patients [89] and 3-week treatment of COPD
patients with ghrelin (2 μg/kg twice a day) significantly
increased food intake, body weight, lean body mass, and
muscle strength [11]. Intriguingly, ghrelin further increased
plasma levels of GH while epinephrine levels are decreased,
thus indicating a decrease of sympathetic nerve activity due
to ghrelin treatment [11]. Ghrelin-mediated modulation of the
GH/IGF-1 axis might be important for pulmonary cachexia as
GH treatment has previously been shown to increase muscle
mass in patients with COPD [90]. Together, these data
support the potential of ghrelin to promote food intake and
body weight gain in patients with pulmonary cachexia.
5 Chronic heart failure
Chronic heart failure is a major public health problem
affecting approximately 5 million Americans with nearly
500,000 new cases every year [91]. Cardiac cachexia is
observed in 10–15% of patients with CHF [85] and cachexia
in these patients is associated with a poor prognosis and an
increased mortality rate compared to non-cachexia patients
[92]. Accordingly, mortality rates in patients with CHF are as
high as 50% in patients with cachexia compared to 17% in
patients without cachexia [1, 92].
Left ventricular dysfunction and left ventricular remod-
eling (dilatation and wall thinning) are frequently observed
in patients with advanced stages of CHF [86, 93]. Growth
hormone and IGF-1 are important physiological regulators
of myocardial growth and performance [94, 95]a n d
patients with CHF show typically elevated serum levels of
GH and normal to decreased levels of IGF-1 [96, 97], thus
indicating that alterations of the GH/IGF-1 axis might be
implicated in the myocardial dysfunction and cachexia in
these patients. Several studies have assessed the therapeutic
potential of GH supplementation in the treatment of CHF,
revealing that GH treatment improves left ventricular
dysfunction and cardiac performance in both CHF rats
[98–100] and patients with CHF [101]. Due to ghrelins
beneficial effects on energy metabolism and GH/IGF-1
secretion it is suggested that ghrelin might improve cardiac
performance and cachexia in CHF patients through GH-
dependent and -independent mechanisms [91, 102]. Ac-
cordingly, 3-week treatment of CHF rats with ghrelin
(100 μg/kg/day) increased serum GH and IGF-1 levels
and promoted body weight gain and improved cardiac
performance by increasing the diastolic thickness of the
non-infarcted posterior wall and by inhibition of left
ventricular enlargement [102]. In line with these observa-
tions, twice-daily treatment of CHF patients with ghrelin at
doses of 2 μg/kg for 3 weeks improved cardiac perfor-
mance and attenuated cachexia by increasing muscle
strength and lean body mass [10]. Ghrelin further inhibits
apoptosis of cardiomyocytes and endothelial cells in vitro
[103] and decreases arterial pressure while increasing
cardiac output in CHF rats [102] and healthy humans
[104]. Together, these data indicate that ghrelin has
beneficial effects on cardiovascular performance and
cachexia through GH-dependent and independent mecha-
nisms and that modulation of the ghrelin system is an
interesting target for the treatment of myocardial dysfunc-
tion and cachexia in patients with CHF.
6 Renal failure
Anorexia and cachexia are frequently observed in patients
with chronically decreased renal function, such as in
patients with ESRD or chronic kidney disease [105, 106].
Renal insufficiency in these patients is often accompanied
by increased serum levels of pro-inflammatory cytokines,
such as TNFα and IL-6 [105, 106], which promote tissue
wasting and cachexia by, e.g., inhibition of myogenesis and
stimulation of skeletal muscle protein breakdown [5, 7].
Plasma levels of desacyl- and total ghrelin are elevated
in patients with renal failure [107–110] and decline upon
dialysis treatment [109, 110]. As the kidney is the primary
site of ghrelin clearance [111] it is likely that ghrelin
accumulates in these patients as a result of renal insuffi-
ciency [13, 112]. Several studies have assessed the
therapeutic potential of ghrelin in the treatment of anorexia
and cachexia in patients with renal failure [112–114].
Continuous infusion of nephrectomized rats for 14 days
with either ghrelin or ghrelin analogues (BIM-28125 and
BIM-28131, 150 nmol/kg/day) significantly increased food
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pro-inflammatory cytokines compared to saline treated
controls [112]. Accordingly, in a randomized, double blind,
placebo-controlled crossover design, in which patients with
peritoneal dialysis where treated with a single subcutaneous
injection of ghrelin (3.6 nmol/kg), ghrelin increased
immediate food intake by 57% compared to saline treated
controls [113]. A similar effect on food intake was found in
a double-blinded randomized crossover study where mal-
nourished dialysis patients were treated for 1 week with
12 μg/kg/day of ghrelin [114].
7 Conclusion
Total ghrelin-like immunoreactivity in plasma is typi-
cally elevated in patients with anorexia nervosa as well
as in cachexia associated with chronic heart failure
[115, 116], renal failure [107, 117], chronic obstructive
pulmonary disease [85, 89], and various forms of cancer
[71, 118, 119]. Hyperghrelinemia in these patients may
reflect a compensatory response to counteract the weight
loss associated with skeletal muscle and fat mass
wasting.
Several animal studies support the potential of ghrelin
and ghrelin analogues to promote food intake and body
weight gain in cachexia associated with heart failure [91,
102, 120, 121], chronic kidney disease [112] and cancer
[67, 68, 70]. Accordingly, several human trials report
improvements of appetite and body mass upon ghrelin
treatment in patients with anorexia nervosa [64]a n d
cachexia associated with renal failure [113, 114], chronic
heart failure [10], chronic obstructive pulmonary disease
[11], and cancer [73]. Notably, as yet all studies support
the safety and tolerability of ghrelin treatment and no
serious adverse side effects have so far been reported
[73, 74]. Together, these data indicate that the endogenous
ghrelin system represents an attractive target for the
treatment of pathologically reduced body weight and
tissue wasting, the key clinical feature of cachexia.
However, further studies in larger populations are neces-
sary to clarify the long-term effects of ghrelin treatment
and to assess the possible impact of ghrelin and ghrelin
induced growth factor release on tumor growth and
carcinogenesis.
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